Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The Chinese patients with chronic hepatitis C have a different genetic background, which had been demonstrated to significantly influence their responses to pegylated interferon and ribavirin. In this study, Chinese patients with Hepatitis C Virus genotype 1, 2/3, 6 infection were treated with pegylated interferon and ribavirin. Their response was compared amongst different genotypes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Genotype 6 | Experimental | Genotype 6 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks |
|
| Genotype 1 | Experimental | Genotype 1 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks |
|
| Genotype 2/3 | Experimental | Genotype 2/3 chronic hepatitis C patients will be treated with Peginterferon alfa-2a/2b plus ribavirin for 24 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 48-weeks course | Drug | patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Sustained virological response (SVR) | Undetectable HCVRNA in serum(<15IU/ml) 24 weeks after the end of treatment | 24 weeks after the end of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Change in health related quality as measured by short form 36 (SF-36) from baseline to 24 weeks after the end of treatment | 24 weeks after the end of treatment | |
| Sick leave in patients treated for 24 or 48 weeks treatment | 48 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Eighth People's Hospital of Guangzhou | Guangzhou | Guangdong | 510000 | China | ||
| The Third Affliated Hospital of Sun Yat-sen University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Ribavirin | Drug | patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks |
|
| Peginterferon alfa2a | Drug | patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks |
|
| Ribavirin | Drug | patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks |
|
| Guangzhou |
| Guangdong |
| 510630 |
| China |
| Zhongshan second people's hospital | Zhongshan | Guangdong | China |
| ID | Term |
|---|---|
| D019698 | Hepatitis C, Chronic |
| ID | Term |
|---|---|
| D006526 | Hepatitis C |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D006525 | Hepatitis, Viral, Human |
| D014777 | Virus Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D006521 | Hepatitis, Chronic |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D012254 | Ribavirin |
| C100416 | peginterferon alfa-2a |
| ID | Term |
|---|---|
| D012263 | Ribonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
Not provided
Not provided